IQVIA Holdings (IQV)

NYSE Market Open

IQVIA Holdings Inc. provides data, analytics, technology, and outsourced research services to the global life sciences industry. The company was created through the 2016 combination of Quintiles, a major clinical research organisation, and IMS Health, a healthcare information and analytics specialist. That merger gave IQVIA a distinctive position at the intersection of clinical development, real-world healthcare data, and commercial execution.

Its Research & Development Solutions business helps biopharmaceutical companies plan and run clinical programmes. Services can cover trial design, patient recruitment, site selection and management, clinical monitoring, laboratory and testing support, real-world evidence studies, and assistance with regulatory processes. By outsourcing this work to IQVIA, drug developers can access global infrastructure, therapeutic expertise, and operational scale without building every capability internally.

IQVIA also supports companies after and around product launch through its technology and commercial services. These offerings include healthcare analytics, market access support, sales and medical outsourcing, and software platforms used to understand treatment patterns, physician behaviour, patient populations, and product performance. The company’s data assets and analytical tools are used by pharmaceutical manufacturers, biotechnology companies, medical technology firms, payers, providers, and public-sector organisations.

The company’s role is tied closely to the complexity of modern healthcare. Drug development requires larger data sets, more specialised trial designs, and stronger evidence of safety, efficacy, value, and real-world outcomes. IQVIA serves that demand by combining contract research capabilities with healthcare intelligence, making it a key service provider for companies seeking to develop, approve, and commercialise medicines globally.

181.61 USD
−1.65 (-0.90%)

Last updated

Market Cap
30.62B
P/E
22.11
P/FCF
14.47
P/S
1.84
Enterprise Value
44.5B
Sector
Industrials
Industry
Commercial Physical and Biological Research
Address
2400 ELLIS ROAD, DURHAM, NC, 27703
GlobeNewswire Inc.

Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China

11-May-2026, 16:00 PM
GlobeNewswire Inc.

Clinical Trial Management System Research Report 2026: $4.2 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

24-Apr-2026, 14:56 PM
GlobeNewswire Inc.

Clinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

24-Apr-2026, 14:53 PM
GlobeNewswire Inc.

Clinical Trials Support Software Solutions in a $34.15B Trial Economy by 2035

18-Feb-2026, 20:00 PM
GlobeNewswire Inc.

Why Clinical Data Analytics Is Becoming One of Healthcare’s Fastest-Growing Markets?

19-Jan-2026, 20:00 PM
GlobeNewswire Inc.

$1.55 Bn Disease Registry Software Global Markets, 2019-2024, 2024-2029F, 2034F: Shift to Value-based Care and Addressing Rare Diseases Offer Further Growth Avenues

12-Jan-2026, 21:00 PM
GlobeNewswire Inc.

Electronic Clinical Outcome Assessment Solutions Market Projected to Reach USD 5.64 Billion by 2032 at a CAGR of 15.3% - SNS Insider

14-Dec-2025, 18:10 PM
GlobeNewswire Inc.

Certara Appoints Jon Resnick as Chief Executive Officer

11-Dec-2025, 16:00 PM
GlobeNewswire Inc.

Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response

04-Dec-2025, 23:47 PM
GlobeNewswire Inc.

Generic Drug CRO Market Size to Climb to USD 11.73 Billion by 2034, reports Towards Healthcare

25-Nov-2025, 17:00 PM
GlobeNewswire Inc.

Real World Evidence Solutions Research and Forecast Report 2025-2030: Growth Opportunities in Emerging Markets and Increased Focus on End-To-End Rwe Services, & Personalized and Precision Medicine

01-Oct-2025, 19:00 PM
GlobeNewswire Inc.

Life Sciences Real-World Evidence Solutions Company Benchmark Report 2025: Vendor Evaluation Emphasizes Data Integration, Analytics, and Patient-Centric Approaches

19-Jun-2025, 13:33 PM
GlobeNewswire Inc.

Questex’s Fierce Biotech Announces 2025 Fierce CRO Award Finalists

14-May-2025, 23:00 PM
GlobeNewswire Inc.

Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Call for Submissions

06-May-2025, 23:00 PM
GlobeNewswire Inc.

eClinical Solutions Market Size to Lead USD 40,500 Million by 2034, Growth in the Biopharmaceutical and Pharmaceutical Industry

06-May-2025, 20:00 PM
GlobeNewswire Inc.

AI in Clinical Settings Research Report 2024 and Global Forecasts 2025-2030 Featuring IQVIA, AiCure, Google, DeepScribe, Siemens Healthineers, Nuance Communications, Care.ai, Qure AI, NVIDIA, Arm

30-Jan-2025, 15:52 PM
GlobeNewswire Inc.

Revolutionizing Pharma: The Impact of Big Data and Technological Advances on the Pharma Industry

31-Dec-2024, 15:52 PM
GlobeNewswire Inc.

Large Molecule Bioanalytical Testing Services Market Size, Share & Trends Analysis Report 2025-2030, Featuring Laboratory Corporation of America, IQVIA, Syneous Health, SGS, WuXi AppTec and Other Major Players

02-Dec-2024, 14:56 PM
GlobeNewswire Inc.

Clinical Trial Patient Recruitment Services Market to Hit US$ 19.1 Billion by 2031 at 8.2% CAGR, Says CoherentMI

16-Oct-2024, 19:02 PM
GlobeNewswire Inc.

Life Science Analytics Market Size to Surpass US$ 23.61 Billion by 2033, The Brainy Insights

29-Aug-2024, 18:00 PM
Market Cap
30.62B
Enterprise Value
44.5B
P/E
22.11
P/B
4.92
P/S
1.84
EV / EBITDA
12.74
EV / Sales
2.68
EPS
8.3
Dividend Yield
0%
P/FCF
14.47
P/CF
11.32
Free Cash Flow
2.12B
ROE
22.26%
ROA
4.67%
Debt / Equity
2.55
Current Ratio
0.75
Quick Ratio
0.75
Cash
0.23
Avg Volume
1.79M
Fundamentals Snapshot Price
183.45

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 4.15B 4.36B 4.1B 4.02B 3.83B
Gross profit 1.36B 1.44B 1.37B 1.32B 1.3B
Operating income 514M 627M 553M 506M 496M
EBITDA 853M 968M 859M 814M 790M
Net income 274M 514M 331M 266M 249M
Basic EPS 1.63 3.01 1.94 1.55 1.42
Diluted EPS 1.61 2.98 1.93 1.54 1.4

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 29.68B 29.94B 28.73B 28.63B 27.32B
Total liabilities 23.33B 23.31B 22.44B 22.85B 21.34B
Total equity 6.35B 6.63B 6.29B 5.79B 5.99B
Cash & equivalents 1.95B 1.98B 1.81B 2.04B 1.74B
Current assets 6.22B 6.25B 5.98B 6.35B 5.91B
Current liabilities 8.33B 8.34B 8.51B 7.57B 7.18B

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow 618M 735M 908M 443M 568M
Investing cash flow -196M -1.1B -550M -346M -305M
Financing cash flow -433M 535M -572M 145M -258M
Change in cash -33M 166M -225M 299M 38M
Kind Filing Date Link
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — Fasano Jim View Filing
form 4 Form 4 — GOGGINS COLLEEN A View Filing
form 4 Form 4 — Wims Morris Leslie View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
edgar index 10-Q — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
edgar index S-8 — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
form 4 Form 4 — Burt Carol View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — Fasano Jim View Filing
form 4 Form 4 — GOGGINS COLLEEN A View Filing
form 4 Form 4 — LEONARD JOHN M View Filing
form 4 Form 4 — Kaelin William G Jr View Filing
form 4 Form 4 — Wims Morris Leslie View Filing
form 4 Form 4 — Stamps Sheila A View Filing
edgar index SCHEDULE 13G/A — IQVIA HOLDINGS INC. View Filing
edgar index DEF 14A — IQVIA HOLDINGS INC. View Filing
edgar index DEFA14A — IQVIA HOLDINGS INC. View Filing
edgar index ARS — IQVIA HOLDINGS INC. View Filing
edgar index 10-K — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
form 4 Form 4 — Fedock Michael J. View Filing
form 4 Form 4 — Haas Bernd View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — Fasano Jim View Filing
form 4 Form 4 — GOGGINS COLLEEN A View Filing